Chronic Inhibition of CYP3A is Temporarily Reduced by Each Hemodialysis Session in Patients With End‐Stage Renal Disease
Open Access
- 1 May 2020
- journal article
- research article
- Published by Wiley in Clinical Pharmacology & Therapeutics
- Vol. 108 (4), 866-873
- https://doi.org/10.1002/cpt.1875
Abstract
Drug dosing is challenging in patients with end‐stage renal disease (ESRD). Not only is renal drug elimination reduced, but nonrenal clearance pathways are also altered. Increasing evidence suggest that uremia impacts drug metabolizing enzymes and transporters leading to changes in nonrenal clearance. However, the exact mechanisms are not yet fully understood, and the acute effects of dialysis are inadequately investigated. We prospectively phenotyped cytochrome P450 3A (CYP3A) (midazolam) and P‐glycoprotein (P‐gp)/organic anion‐transporting proteins (OATP) (fexofenadine) in twelve patients on chronic intermittent hemodialysis; a day after (“clean”) and a day prior to (“dirty”) dialysis. Unbound midazolam clearance decreased with time after dialysis; median (range) reduction of 14% (‐3% ‐ 41%) from “clean” to “dirty” day (P=0.001). Fexofenadine clearance was not affected by time after dialysis (P=0.68). In conclusion, changes in uremic milieu between dialysis sessions induce a small, direct inhibitory effect on CYP3A activity, but do not alter P‐gp/OATP activity.Keywords
This publication has 37 references indexed in Scilit:
- OATP1B1 Polymorphism as a Determinant of Erythromycin DispositionClinical Pharmacology & Therapeutics, 2012
- Albumin-binding capacity (ABiC) is reduced in patients with chronic kidney disease along with an accumulation of protein-bound uraemic toxinsNephrology Dialysis Transplantation, 2011
- Down-Regulation of Liver Drug-Metabolizing Enzymes in a Murine Model of Chronic Renal FailureDrug Metabolism and Disposition, 2009
- Impact of OATP transporters on pharmacokineticsBritish Journal of Pharmacology, 2009
- ESRD Impairs Nonrenal Clearance of Fexofenadine but not MidazolamJournal of the American Society of Nephrology, 2009
- Effects of Chronic Renal Failure on Liver Drug TransportersDrug Metabolism and Disposition, 2007
- Down-Regulation of Intestinal Drug Transporters in Chronic Renal Failure in RatsThe Journal of pharmacology and experimental therapeutics, 2006
- Hemodialysis Acutely Improves Hepatic CYP3A4 Metabolic ActivityJournal of the American Society of Nephrology, 2006
- Effects of serum from patients with chronic renal failure on rat hepatic cytochrome P450British Journal of Pharmacology, 2005
- EFFECTS OF UREMIC TOXINS ON HEPATIC UPTAKE AND METABOLISM OF ERYTHROMYCINDrug Metabolism and Disposition, 2004